Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France.

< BACK TO ARCHIVE


2022 Apr 01


Allergy Asthma Clin Immunol


http://www.ncbi.nlm.nih.gov/pubmed/35365234?dopt=Abstract


18


1

Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France.

Authors

Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France.
Fain O, Du-Thanh A, Gobert D, Launay D, Inhaber N, Boudjemia K, Aubineau M, Sobel A, Boccon-Gibod I, Weiss L, Bouillet L
Allergy Asthma Clin Immunol. 2022 Apr 01; 18(1):30.
PMID: 35365234.

Abstract

Hereditary angioedema (HAE) is associated with a heavy burden of illness.
Read This Paper